LOS ANGELES, Nov. 27, 2012 /PRNewswire/ -- In an effort to accommodate growing demand, Akeso Health Sciences, L.L.C. is pleased to announce the availability of MigreLief Triple Therapy with Puracol™, at CVS Pharmacy stores nationwide and on CVS.com. Both MigreLief Original Formula and MigreLief+M the breakthrough menstrual migraine formula hit the shelves of CVS this week.
Researchers are finding the more migraines a patient gets, the more susceptible they become to having more. Migraine sufferers are becoming increasingly aware of the importance of maintaining the already normal and healthy cerebrovascular function they have when they are migraine free. Staying well rather than trying to get well taking pain medications is the goal.*
MigreLief is a non-prescription, comprehensive supplement for chronic migraine sufferers and formulated to maintain normal cerebrovascular function by addressing the underlying nutritional deficiencies and imbalances common to many migraine sufferers.* Recommended by neurologists and headache specialists, MigreLief is safe for men, women and children over 2 years old, is free of harmful side-effects and may be safely combined with other migraine medications.
"We have a very large and loyal online community of customers who have asked for more convenient access to MigreLief through the stores they frequent most," stated Curt Hendrix, Chief Science Officer of Akeso Health Sciences and the scientist who created MigreLief."With over 7,000 CVS stores in the United States, we are thrilled MigreLief will be more accessible to our followers and even more pleased that higher visibility will give 30 million migraine sufferers across the U.S. a greater opportunity to discover this safe and effective, non-prescription, nutritional alternative. MigreLief's patented formulation; Puracol, a proprietary blend of unique feverfew sources, magnesium from two sources and high dose, highly absorbable riboflavin (Vitamin B-2) have all independently shown significant benefits to chronic migraine sufferers.